Last mentioned: Mar 8, 2026
Expected Earnings Call
Anticipated date for official Q4 2025 financial disclosures and 2026 guidance.
Earnings Preview
Seeking Alpha releases Q4 2025 earnings preview for RAIL and CHRS.
Q4 2025 Preview
Analysts set expectations for oncology-driven revenue growth.
Steady Demand
Company reports steady demand for specialized railcars amid industrial recovery.
Manufacturing Shift
FreightCar America continues transition of manufacturing to Mexico to reduce overhead.
Loqtorzi Launch
Full commercial ramp-up of the first-in-class PD-1 for NPC.
Yusimry Divestiture
Sale of adalimumab biosimilar to HK King-Friend for $40M.
Cimerli Divestiture
Coherus sells its ranibizumab biosimilar to Sandoz for $170M.
Coherus BioSciences is navigating a high-stakes pivot toward its innovative oncology portfolio, while FreightCar America seeks to capitalize on a robust railcar replacement cycle. Both companies face critical Q4 2025 earnings calls that will define their 2026 growth trajectories and capital allocation strategies.
Coherus BioSciences is set to report Q4 2025 earnings as it completes its strategic transition into a pure-play oncology firm. Investors are focused on the commercial ramp of Loqtorzi and the market share recovery of the Udenyca franchise following the launch of its Onbody injector.
Coherus BioSciences is set to report Q4 2025 results, marking a critical milestone in its transition from a biosimilar-focused firm to an innovative oncology leader. Investors are closely monitoring the commercial ramp of Loqtorzi and the market share gains of the Udenyca On-Body Injector following significant portfolio divestitures.
FreightCar America's upcoming Q4 2025 earnings report will serve as a critical barometer for the health of North American rail logistics and equipment demand. As the company navigates a shifting industrial landscape, its performance reflects broader trends in freight volume and infrastructure investment.